Compugen Ltd.

Company Overview

Founded in 1993, Compugen is a clinical-stage drug discovery and development company. It has a broadly applicable, predictive discovery infrastructure, which is being used to advance a therapeutic pipeline that consists of many early-stage immune-oncology programs. The company uses an integrated infrastructure of proprietary scientific and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. Compugen’s business model includes collaborations that cover the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of R&D agreements. This provides Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing.

Financial Highlights (FY 2025)

Company's Business Segments

• Life Science : The company provides clinical-stage cancer immunotherapies developed using its AI-powered computational discovery platform, Unigen.